Healthcare investors’ attention in recent weeks has been riveted on the priciest stocks in the sector:
Eli Lilly
with its heart-stopping market value of $412 billion—the most ever for a pure-play biopharma company—and
Novo Nordisk
not far behind with a $377 billion market value.
